- Oops!Something went wrong.Please try again later.
LAFAYETTE, La., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced another published non-invasive ventilation study led by Dr. William Frazier, Viemed’s Chief Medical Officer. The study, entitled “Noninvasive Ventilation at Home Reduces Mortality in COPD With CRF”, was published on September 15, 2021, in the on-line edition of The American Journal of Managed Care, a respected, peer reviewed journal. (https://www.ajmc.com/view/noninvasive-ventilation-at-home-reduces-mortality-in-copd-with-crf)
Patients with chronic respiratory failure secondary to chronic obstructive pulmonary disease (“COPD-CRF”) have limited treatment options and poor health outcomes. This study examined the effect of noninvasive ventilation at home (“NIVH”) on all-cause mortality, hospitalizations, and emergency department (“ED”) visits in patients with COPD-CRF. The results demonstrated that patients with COPD-CRF who received NIVH had statistically significant and clinically meaningful reductions in hospitalizations and ED visits compared with patients not treated with NIVH. Furthermore, the data suggests that earlier NIVH treatment following CRF diagnosis is associated with a large reduction in all-cause mortality.
The highlights of the results are as follows:
Patients with COPD and CRF who were prescribed NIVH had statistically significant reductions in risk of death (38.3%), hospitalizations (21.0%), and ED visits (42.9%) compared with similar patients not treated with NIVH.
NIVH is associated with a 1-year risk difference of 13.0% for mortality, 8.4% for first hospitalization, and 17.6% for first ED visit, yielding relative risk reductions of 30.7%, 12.9%, and 20.1%, respectively. The numbers needed to treat are 7.7 to prevent a death, 12.0 to prevent a first hospitalization, and 5.7 to prevent a first ED visit.
All data for the study was obtained from the Medicare Limited Data Set and included patients who were diagnosed with COPD and CRF between 2012 and 2017.
“We are very pleased to once again see published evidence that supports the clinical efficacy of NIVH on the highest risk, chronically ill respiratory patients, and are excited to continue to share these results with the medical community,” said Casey Hoyt, Viemed’s CEO. “These results confirm the findings of a separate study (https://doi.org/10.1016/j.rmed.2020.106291) published in December 2020 which used different statistical methods and studied a different patient population than that used in the current study. While both of these studies used data from the Medicare Limited Data set, our ongoing sponsored study on outcomes associated with NIVH use in COPD-CRF includes data from the complete Medicare data set from 2016 through 2020. We expect to be sharing the results with physicians, payors, patients, and the rest of our industry peers in the near future.”
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Chief Operating Officer
Viemed Healthcare, Inc.
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, or “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s expectations on sharing study results in the future, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company’s novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.